Lead Product(s): Imotope
Therapeutic Area: Immunology Product Name: Undisclosed
Highest Development Status: Undisclosed Product Type: Peptide
Partner/Sponsor/Collaborator: Pfizer Inc
Deal Size: $25.0 million Upfront Cash: Undisclosed
Deal Type: Series B Financing February 17, 2021
The funding will allow the company advance its lead Imotope candidate for Type 1 Diabetes into phase 2 as well as four other programs in Multiple Sclerosis, Neuromyelitis Optica Spectrum Disorders, Celiac Disease, and Rheumatoid Arthritis.